BIIB (STOCKS)
Biogen Inc. Common Stock
$191.200000
+2.210000 (+1.17%)
Prev close: $188.990000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Christopher A. Viehbacher
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $28,051.52M
- Employees
- 7,605
- P/E (TTM)
- 21.50
- P/B (TTM)
- 1.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
11
Buy
21
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.99 | $1.65 | +0.3436 | +20.87% |
|
Sep 2025 (Q3)
|
$4.81 | $3.96 | +0.8505 | +21.48% |
|
Jun 2025 (Q2)
|
$5.47 | $3.94 | +1.5325 | +38.92% |
|
Mar 2025 (Q1)
|
$3.02 | $2.58 | +0.4449 | +17.28% |
Financial Statements
| Revenues | $9.89B |
| Benefits Costs and Expenses | $8.33B |
| Cost Of Revenue | $2.40B |
| Costs And Expenses | $8.33B |
| Gross Profit | $7.49B |
| Nonoperating Income/Loss | -$305.60M |
| Operating Expenses | $5.93B |
| Selling, General, and Administrative Expenses | $2.43B |
| Other Operating Expenses | $3.50B |
| Operating Income/Loss | $1.56B |
| Income/Loss From Continuing Operations After Tax | $1.29B |
| Income/Loss From Continuing Operations Before Tax | $1.56B |
| Income Tax Expense/Benefit | $263.60M |
| Income Tax Expense/Benefit, Current | -$98.00M |
| Income Tax Expense/Benefit, Deferred | $361.60M |
| Interest Expense, Operating | $267.50M |
| Net Income/Loss | $1.29B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $1.29B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.29B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $8.83 |
| Diluted Earnings Per Share | $8.79 |
| Basic Average Shares | 146,500,000 |
| Diluted Average Shares | 147,100,000 |
| Assets | $29.44B |
| Current Assets | $8.97B |
| Inventory | $2.17B |
| Other Current Assets | $6.81B |
| Noncurrent Assets | $20.47B |
| Fixed Assets | $3.06B |
| Intangible Assets | $9.18B |
| Other Non-current Assets | $8.23B |
| Liabilities | $11.18B |
| Current Liabilities | $3.35B |
| Accounts Payable | $432.00M |
| Other Current Liabilities | $2.92B |
| Noncurrent Liabilities | $7.83B |
| Long-term Debt | $6.29B |
| Other Non-current Liabilities | $1.55B |
| Equity | $18.26B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $18.26B |
| Liabilities And Equity | $29.44B |
| Net Cash Flow From Operating Activities | $2.20B |
| Net Cash Flow From Operating Activities, Continuing | $2.20B |
| Net Cash Flow From Investing Activities | -$1.37B |
| Net Cash Flow From Investing Activities, Continuing | -$1.37B |
| Net Cash Flow From Financing Activities | -$301.90M |
| Net Cash Flow From Financing Activities, Continuing | -$301.90M |
| Exchange Gains/Losses | $101.90M |
| Net Cash Flow | $633.50M |
| Net Cash Flow, Continuing | $531.60M |
| Comprehensive Income/Loss | $1.25B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.25B |
| Other Comprehensive Income/Loss | -$45.80M |
| Other Comprehensive Income/Loss Attributable To Parent | -$45.80M |